Off-Label Drug Use in Oncology
https://doi.org/10.24060/2076-3093-2022-12-2-164-171
Abstract
The off-label use of medicines is a routine clinical practice of oncology, especially in malignant-tumour patients with no treatment alternatives left when registered-drug options have been exhausted or standard therapies reveal contraindications. The recent shift from single-gene assays to multigene panels powered by full-exome or -genome sequencing expands the capacity of precision therapy, leading to a wider agnostic off-label use of targeted drugs for detecting a particular molecular genetic disorder. Studies of the off-label drug use in oncology will clarify the feasibility and safety of such prescriptions in patients with rare forms of malignancy when registered therapies have been exhausted or standard treatment reveals contraindications. This article examines the prevalence and landscape of off-label drug use in cancer patients and elaborates on the off-label principle. The paper presents a critical reflection on the off-label use of medicines in oncology.
About the Authors
E. V. Karabina
Tula Regional Clinical Oncology Dispensary;
Bashkir State Medical University
Russian Federation
Russian Federation
Department of Anticancer Drug Therapy, Department of Oncology with courses of Oncology and Pathological Anatomy for Advanced Professional Education
Ufa
D. D. Sakaeva
Bashkir State Medical University;
Mother and Child Clinical Hospital
Russian Federation
Russian Federation
Dr. Sci. (Med.), Prof., Department of Pharmacology with a course of Clinical Pharmacology
Ufa
O. N. Lipatov
Bashkir State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Prof., Department of Oncology with courses of Oncology and Pathological Anatomy for Advanced Professional Education
Ufa
References
1. Martsevich S.Y., Navasardjan A.R., Komkova N.A. Off-label prescribing. possible causes, types and consequences. Legal regulation in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2017;13(5):667–74 (In Russ). DOI: 10.20996/1819-6446-2017-13-5-667-674
2. Bunyatyan N.D., Korobov N.V., Uteshev D.B., Yavorskiy A.N. Off-label drugs: some aspects of their use and promotion. Medical Technologies. Assessment and Choice. 2010;2:49–53 (In Russ.).
3. Pereverzev A.P., Lepakhin V.K. Off-label use of drugs — important problem of modern pharmacotherapy. Ural Medical Journal. 2013;3(108):133–6 (In Russ.).
4. Braillon A., Lexchin J. Innovation and off-label use, the French case and more. Br J Clin Pharmacol. 2019;85(10):2446–7. DOI: 10.1111/bcp.13993
5. Khadartsev A.A. Ivanov D.V., Khadartseva K.A. Legal aspects off-labeluse of drugs (literature review). Journal of New Medical Technologies. 2020;3:115–23 (In Russ.). DOI: 10.24411/2075-4094-2020-16654
6. Wittich Ch.M., Burkle Ch.M., Lanier W.L. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982–90. DOI: 10.1016/j.mayocp.2012.04.017
7. Stafford R.S. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427–9. DOI: 10.1056/NEJMp0802107
8. The Pharma Marketing Glossary [cited 2011 Feb 5]. In: Pharma Marketing Network. Available from: http://www.glossary.pharma-mkting.com/offlabel.htm
9. Somova M.N., Batishcheva G.A. Legal aspects of prescribing off-label. Applied Information Aspects of Medicine. 2016;19(3):139–43 (In Russ.).
10. Tsygankova O.V., Batluk T.I., Latyntseva L.D., Platonov D.Y., Akhmedzhanov N.M. Legal and medical aspects of off-label medication use. Point of view. Rational Pharmacotherapy in Cardiology. 2019;15(1):130–4 (In Russ.). DOI: 10.20996/1819-6446-2019-15-1-130-134
11. Rusz C.M., Ősz B.E., Jîtcă G., Miklos A., Bătrînu M.G., Imre S. Offlabel medication: from a simple concept to complex practical aspects. Int J Environ Res Public Health. 2021;18(19):10447. DOI: 10.3390/ijerph181910447
12. Volskaya E. Narrow limits of freedom: off label use of medicinal products. Remedium. 2017;7–8:6–10 (In Russ.). DOI: 10.21518/1561-5936-2017-7-8-6-10
13. Saiyed M.M., Ong P.S., Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251–8. DOI: 10.1111/jcpt.12507
14. Zhang B., Song Y., Fu Y., Zhu B., Wang B., Wang J. Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China. BMC Cancer. 2020;20(1):86. DOI: 10.1186/s12885-020-6583-3
15. Nikfarjam A., Ransohoff J.D., Callahan A., Polony V., Shah N.H. Profiling off-label prescriptions in cancer treatment using social health networks. JAMA Open. 2019;2(3):301–5. DOI: 10.1093/jamiaopen/ooz025
16. Lim M., Shulman D.S., Roberts H., Li A., Clymer J., Bona K., et al. Offlabel prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020;9(18):6658–66. DOI: 10.1002/cam4.3349
17. Souza J.A.de, Duong Y.Y. Off-label immunotherapy prescription: financial implications for payers and patients. J Clin Oncol. 2017;35(8,Suppl.):6. DOI: 10.1200/JCO.2017.35.8_suppl.6
18. Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol. 2016;7(2):253–7. DOI: 10.5306/wjco.v7.i2.253
19. McCafferty J., Grover K., Li L., Li Zh., Fink M.Y., Goldsweig H., et al. A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients. J Clin Oncol. 2019;37(Suppl. 15):e18031. DOI: 10.1200/JCO.2019.37.15_suppl.e18031
20. Herbrand A.K., Schmitt A.M., Briel M., Ewald H., Goldkuhle M., Diem S., et al. Association of supporting trial evidence and reimbursement for off-label use of cancer drugs. JAMA Netw Open. 2021;4(3):e210380. DOI: 10.1001/jamanetworkopen.2021.0380
21. Smieliauskas F., Sharma H., Hurley C., de Souza J.A., Shih Y.T. State insurance mandates and off-label use of chemotherapy. Health Econ. 2018;27(1):e55–70. DOI: 10.1002/hec.3537
22. Herrero Fernandez M., Molina Villaverde R., Arroyo Yustos M., Navarro Expósito F., Lopez Gonzalez J.L., Luque Infantes M.R., et al. The off-label use of antineoplastics in oncology is limited but has notable scientific support in a university hospital setting. Front Pharmacol. 2019;10:1210. DOI: 10.3389/fphar.2019.01210
23. Upadhyay V.A., Johnson B.E., Landman A.B., Hassett M.J. Real-world analysis of off-label use of molecularly targeted therapy in a large academic medical center cohort. JCO Precis Oncol. 2022;6:e2100232. DOI: 10.1200/PO.21.00232
24. Wei G., Wu M., Zhu H., Han S., Chen J., Zhai C., et al. Off-label use of antineoplastic drugs to treat malignancies: evidence from China based on a nationwide medical insurance data analysis. Front Pharmacol. 2021;12:616453. DOI: 10.3389/fphar.2021.616453
25. Gordon N., Goldstein D.A., Tadmor B., Stemmer S.M., Greenberg D. Factors associated with off-label oncology prescriptions: the role of cost and financing in a universal healthcare system. Front Pharmacol. 2021;12:754390. DOI: 10.3389/fphar.2021.754390
26. Bun S., Yonemori K., Sunadoi H., Nishigaki R., Noguchi E., Okusaka T., et al. Safety and evidence of off-label use of approved drugs at the national cancer center hospital in Japan. JCO Oncol Pract. 2021;17(3):e416–25. DOI: 10.1200/OP.20.00131
27. Eaton A.A., Sima C.S., Panageas K.S. Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-Medicare Data. J Natl Compr Canc Netw. 2016;14(1):57–65. DOI: 10.6004/jnccn.2016.0007
28. Azad N.S., Gray R.J., Overman M.J., Schoenfeld J.D., Mitchell E.P., Zwiebel J.A., et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol. 2020;38(3):214–22. DOI: 10.1200/JCO.19.00818
29. Naing A., Meric-Bernstam F., Stephen B., Karp D.D., Hajjar J., Rodon Ahnert J., et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020;8(1):e000347. DOI: 10.1136/jitc-2019-000347
30. Mangat P.K., Halabi S., Bruinooge S.S., Garrett-Mayer E., Alva A., Janeway K.A., et al. Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol. 2018;2018:10.1200/PO.18.00122. DOI: 10.1200/PO.18.00122
31. Okuma H.S., Yonemori K., Narita S.N., Sukigara T., Hirakawa A., Shimizu T., et al. MASTER KEY Project: powering clinical development for rare cancers through a platform trial. Clin Pharmacol Ther. 2020;108(3):596–605. DOI: 10.1002/cpt.1817
32. Sunami K., Ichikawa H., Kubo T., Kato M., Fujiwara Y., Shimomura A., et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019;110(4):1480–90. DOI: 10.1111/cas.13969
33. Krzyszczyk P., Acevedo A., Davidoff E.J., Timmins L.M., MarreroBerrios I., Patel M., et al. The growing role of precision and personal ized medicine for cancer treatment. Technology (Singap World Sci). 2018;6(3–4):79–100. DOI: 10.1142/S2339547818300020
34. Remon J., Dienstmann R. Precision oncology: separating the wheat from the chaff. ESMO Open. 2018;3(6):e000446. DOI: 10.1136/esmoopen-2018-000446
35. Singh A.P., Shum E., Rajdev L., Cheng H., Goel S., Perez-Soler R., et al. Impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice. Cancers (Basel). 2020;12(5):1156. DOI: 10.3390/cancers12051156
36. de Vries E.G.E., Cherny N.I., Voest E.E. When is off-label off-road? Ann Oncol. 2019;30(10):1536–8. DOI: 10.1093/annonc/mdz445
37. Xu-Monette Z.Y., Zhang M., Li J., Young K.H. PD-1/ PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8:1597. DOI: 10.3389/fimmu.2017.01597
38. Pons-Tostivint E., Latouche A., Vaflard P., Ricci F., Loirat D., Hescot S., et al. Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials. JCO Precis Oncol. 2019;3:1–10. DOI: 10.1200/PO.18.00114
39. Aronson J.K., Ferner R.E. Unlicensed and off-label uses of medicines: Definitions and clarification of terminology. Br J Clin Pharmacol. 2017;83:2615–25. DOI: 10.1111/bcp.13394
40. Vannieuwenhuysen C., Slegers P., Neyt M., Hulstaert F., Stordeur S., Cleemput I., et al. Towards a better managed off-label use of drugs [cited 2021 June 17]. In: Health Services Research (HSR). Brussels: Belgian Health Care Knowledge Centre (KCE); 2015. Available from:https://kce.fgov.be/sites/default/files/atoms/files/KCE_252_Off-label %20drugs_Report.pdf
Review
For citations:
Karabina E.V., Sakaeva D.D., Lipatov O.N. Off-Label Drug Use in Oncology. Creative surgery and oncology. 2022;12(2):164-171. (In Russ.) https://doi.org/10.24060/2076-3093-2022-12-2-164-171
Views:
1351
Email this article 